Free Trial
NASDAQ:NKTX

Nkarta (NKTX) Stock Price, News & Analysis

Nkarta logo
$2.50 +0.02 (+0.81%)
(As of 11/20/2024 ET)

About Nkarta Stock (NASDAQ:NKTX)

Key Stats

Today's Range
$2.40
$2.54
50-Day Range
$2.48
$5.71
52-Week Range
$2.38
$16.24
Volume
1.00 million shs
Average Volume
1.11 million shs
Market Capitalization
$176.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50
Consensus Rating
Buy

Company Overview

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Nkarta Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
44th Percentile Overall Score

NKTX MarketRank™: 

Nkarta scored higher than 44% of companies evaluated by MarketBeat, and ranked 657th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nkarta has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Nkarta has only been the subject of 4 research reports in the past 90 days.

  • Read more about Nkarta's stock forecast and price target.
  • Earnings Growth

    Earnings for Nkarta are expected to decrease in the coming year, from ($1.94) to ($2.01) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nkarta is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nkarta is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nkarta has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Nkarta's valuation and earnings.
  • Percentage of Shares Shorted

    13.56% of the outstanding shares of Nkarta have been sold short.
  • Short Interest Ratio / Days to Cover

    Nkarta has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Nkarta has recently decreased by 8.16%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Nkarta does not currently pay a dividend.

  • Dividend Growth

    Nkarta does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.56% of the outstanding shares of Nkarta have been sold short.
  • Short Interest Ratio / Days to Cover

    Nkarta has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Nkarta has recently decreased by 8.16%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Nkarta has a news sentiment score of -0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Nkarta this week, compared to 2 articles on an average week.
  • Search Interest

    8 people have searched for NKTX on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.
  • MarketBeat Follows

    Only 6 people have added Nkarta to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nkarta insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.70% of the stock of Nkarta is held by insiders.

  • Percentage Held by Institutions

    80.54% of the stock of Nkarta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nkarta's insider trading history.
Receive NKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter.

NKTX Stock News Headlines

HC Wainwright Cuts Nkarta (NASDAQ:NKTX) Price Target to $18.00
Nkarta to Participate in an Upcoming Investor Conference
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…
Nkarta’s Strategic Shift and Financial Strength Bolster Buy Rating
TD Cowen Sticks to Its Buy Rating for Nkarta (NKTX)
Nkarta (NKTX) Stock: Looking For Upside
See More Headlines

NKTX Stock Analysis - Frequently Asked Questions

Nkarta's stock was trading at $6.60 at the beginning of the year. Since then, NKTX stock has decreased by 62.1% and is now trading at $2.50.
View the best growth stocks for 2024 here
.

Nkarta, Inc. (NASDAQ:NKTX) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.15.

Nkarta (NKTX) raised $150 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities served as the underwriters for the IPO.

Top institutional shareholders of Nkarta include Wasatch Advisors LP (2.60%), Geode Capital Management LLC (1.66%), State Street Corp (1.56%) and Barclays PLC (0.33%). Insiders that own company stock include Ra Capital Management, LP, Simeon George, Paul J Hastings, James Trager, David Shook, Alicia J Hager and Ralph Brandenberger.
View institutional ownership trends
.

Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nkarta investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), CrowdStrike (CRWD) and Arista Networks (ANET).

Company Calendar

Last Earnings
8/13/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/20/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NKTX
Fax
N/A
Employees
140
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.50
High Stock Price Target
$25.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+560.0%
Consensus Rating
Buy
Rating Score (0-4)
3.29
Research Coverage
7 Analysts

Profitability

Net Income
$-117,500,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.56 per share

Miscellaneous

Free Float
64,429,000
Market Cap
$176.43 million
Optionable
Optionable
Beta
0.86
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:NKTX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners